Presence of peripheral arthritis and male sex predicting continuation of anti–tumor necrosis factor therapy in ankylosing spondylitis: An observational prospective cohort study from the South Swedish arthritis treatment group register

Abstract

AS patients in this study have an excellent 2-year drug survival rate of 74%. Significant predictors for treatment continuation in this study were male sex and the presence of peripheral arthritis.

Factors associated with ASDAS remission in a long-term study of ankylosing spondylitis patients under tumor necrosis factor inhibitors

“…We have not identified demographic and baseline disease parameters as relevant predictive factors for switching in our patients opposing to previous report that female gender, MTX use, higher BASFI and BASDAI were associated with the second anti-TNF therapy [11]. Although a previous report has shown that peripheral involvement was a predictive factor of switching [18], it was not observed in this study, probably because that represents a common finding in Brazilian axial SpA patients [43]. With regard to the third anti-TNF, we identified that patients with higher BASDAI at the time of introduction of the second anti-TNF agent were more likely to switch to the third TNF inhibitor, suggesting a refractory disease in these patients.…”

Factors associated with ASDAS remission in a long-term study of ankylosing spondylitis patients under tumor necrosis factor inhibitors

“…We have not identified demographic and baseline disease parameters as relevant predictive factors for switching in our patients opposing to previous report that female gender, MTX use, higher BASFI and BASDAI were associated with the second anti-TNF therapy [11]. Although a previous report has shown that peripheral involvement was a predictive factor of switching [18], it was not observed in this study, probably because that represents a common finding in Brazilian axial SpA patients [43]. With regard to the third anti-TNF, we identified that patients with higher BASDAI at the time of introduction of the second anti-TNF agent were more likely to switch to the third TNF inhibitor, suggesting a refractory disease in these patients.…”

Retention rate of subcutaneous TNF inhibitors in axial spondyloarthritis in a multicentre study from the RIC-FRANCE network

“…Concordantly, Brocq et al found retention rates of 76% at 12 months for ETN, whatever the line 34 . Retention rates of treatments at two years were 55% in our study, which is lower than previously reported rates of up to 74% 5 . In our study, retention rate of treatments at three years was 47%, while retention rates of 63% and 76% were reported in the literature in axSpA patients 6 , 35 .…”

Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study

“…This study also confirms the predictive value of high ESR or CRP levels. Our finding that absence of peripheral arthritis is associated with treatment discontinuation is in accordance with Kristensen et al , who reported that patients with peripheral arthritis are more likely to continue TNF-α blocking therapy [9]. In the present study, presence of peripheral arthritis was also independently related to ASAS20 and BASDAI50 response at six months in the presence of age and gender, indicating that concomitant peripheral arthritis is a predictor of both response and continuation of anti-TNF-α treatment.…”

Factors associated with ASDAS remission in a long-term study of ankylosing spondylitis patients under tumor necrosis factor inhibitors

“…We have not identified demographic and baseline disease parameters as relevant predictive factors for switching in our patients opposing to previous report that female gender, MTX use, higher BASFI and BASDAI were associated with the second anti-TNF therapy [11]. Although a previous report has shown that peripheral involvement was a predictive factor of switching [18], it was not observed in this study, probably because that represents a common finding in Brazilian axial SpA patients [43]. With regard to the third anti-TNF, we identified that patients with higher BASDAI at the time of introduction of the second anti-TNF agent were more likely to switch to the third TNF inhibitor, suggesting a refractory disease in these patients.…”

Retention rate of subcutaneous TNF inhibitors in axial spondyloarthritis in a multicentre study from the RIC-FRANCE network

“…Concordantly, Brocq et al found retention rates of 76% at 12 months for ETN, whatever the line 34 . Retention rates of treatments at two years were 55% in our study, which is lower than previously reported rates of up to 74% 5 . In our study, retention rate of treatments at three years was 47%, while retention rates of 63% and 76% were reported in the literature in axSpA patients 6 , 35 .…”

Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study

“…This study also confirms the predictive value of high ESR or CRP levels. Our finding that absence of peripheral arthritis is associated with treatment discontinuation is in accordance with Kristensen et al , who reported that patients with peripheral arthritis are more likely to continue TNF-α blocking therapy [9]. In the present study, presence of peripheral arthritis was also independently related to ASAS20 and BASDAI50 response at six months in the presence of age and gender, indicating that concomitant peripheral arthritis is a predictor of both response and continuation of anti-TNF-α treatment.…”

Factors associated with ASDAS remission in a long-term study of ankylosing spondylitis patients under tumor necrosis factor inhibitors

“…We have not identified demographic and baseline disease parameters as relevant predictive factors for switching in our patients opposing to previous report that female gender, MTX use, higher BASFI and BASDAI were associated with the second anti-TNF therapy [11]. Although a previous report has shown that peripheral involvement was a predictive factor of switching [18], it was not observed in this study, probably because that represents a common finding in Brazilian axial SpA patients [43]. With regard to the third anti-TNF, we identified that patients with higher BASDAI at the time of introduction of the second anti-TNF agent were more likely to switch to the third TNF inhibitor, suggesting a refractory disease in these patients.…”

Retention rate of subcutaneous TNF inhibitors in axial spondyloarthritis in a multicentre study from the RIC-FRANCE network

“…Concordantly, Brocq et al found retention rates of 76% at 12 months for ETN, whatever the line 34 . Retention rates of treatments at two years were 55% in our study, which is lower than previously reported rates of up to 74% 5 . In our study, retention rate of treatments at three years was 47%, while retention rates of 63% and 76% were reported in the literature in axSpA patients 6 , 35 .…”

Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study

“…This study also confirms the predictive value of high ESR or CRP levels. Our finding that absence of peripheral arthritis is associated with treatment discontinuation is in accordance with Kristensen et al , who reported that patients with peripheral arthritis are more likely to continue TNF-α blocking therapy [9]. In the present study, presence of peripheral arthritis was also independently related to ASAS20 and BASDAI50 response at six months in the presence of age and gender, indicating that concomitant peripheral arthritis is a predictor of both response and continuation of anti-TNF-α treatment.…”